IL-6 inhib 
Welcome,         Profile    Billing    Logout  
 61 Companies  48 Products   48 Products   529 Diseases   784 Trials   31084 News 
1027 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rizaben (tranilast) / Kissei, Nuon Therapeutics
ChiCTR2000030002: Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
4
60
China
conventional therapy ;conventional therapy and Tranilast
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Anhui Development and Reform Commission
Novel Coronavirus Pneumonia (COVID-19)
 
 
NCT05130892: Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI

Completed
4
132
RoW
Colchicine, Tranilast, Oridonin
Wuhan Union Hospital, China
NLRP3, hsCRP, Percutaneous Coronary Intervention
02/23
02/23
NCT06307288: Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea

Enrolling by invitation
4
45
RoW
minocycline, tranilast
Second Affiliated Hospital of Xi'an Jiaotong University
Rosacea
06/24
06/24
NCT03923140: A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Recruiting
2
71
RoW
Tranilast, Rizaben
Peking Union Medical College Hospital
Cryopyrin-Associated Periodic Syndromes
04/24
10/24
NCT05626829: Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Recruiting
2
18
RoW
Tranilast
Jian Guan
Nasopharyngeal Carcinoma, Recurrent Cancer
07/24
11/24
TAPES, NCT06643689: Tranilast Vs. Steroids to Prevent Esophageal Stricture () After Endoscopic Resection for Superficial Neoplasms

Not yet recruiting
2
394
RoW
Tranilast, Dexamethasone
Second Affiliated Hospital, School of Medicine, Zhejiang University, The Third People's Hospital of Hangzhou, Xiangya Hospital of Central South University
Esophageal Stricture, Esophageal Neoplasms
12/27
12/28
ChiCTR1800015808: Pilot Clinical Study of Chemo-Cocktail (TTF) for Recurrent Glioblastoma

Recruiting
1
10
 
temmozoldmide+tranilast+fasudil
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, No
Recurrent Glioblastoma
 
 
NCT03490708: A Clinical Study of Tranilast in the Treatment of Mucinoses

Not yet recruiting
1
56
NA
Tranilast
The First Affiliated Hospital with Nanjing Medical University
Mucinoses
06/22
12/22
NCT06689514: Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia

Not yet recruiting
1
30
RoW
alpha receptor antagonist, Low dose Tranilast, High dose Tranilast
Yifeng Jing
Prostatic Hypertrophy, Benign
12/25
12/25
ChiCTR1900028455: A single center, randomized, single blind, controlled trial for tranilast in the treatment of gout

Not yet recruiting
N/A
160
 
take one tranilast capsule (each containing 0.1g of tranilast), three times a day, take it after three meals, treatment for one week ;take 2 capsules of tranilast (0.1g of tranilast per capsule), 3 times / day, after three meals, treatment for 1 week ;Take 1 diclofenac capsule (each containing 50mg of diclofenac) twice a day, take it after breakfast and dinner, and treat for 1 week ;Take 1 colchicine tablet (each tablet contains 0.5mg colchicine), 3 times / day, take after three meals, treatment for 1 week
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Researchers spontaneous
Gout
 
 
gerilimzumab (ARGX-109) / argenx
ACTRN12615001141538: The second healthy volunteer study assessing the safety, tolerability, and pharmacokinetics (blood levels) of gerilimzumab against placebo.

Active, not recruiting
1
18
 
Clinical Network Services Pty Ltd, RuiYi Inc
Rheumatoid Arthritis
 
 
ChiCTR-IIR-17013205: A Pharmacokinetics Study of Gerilimzumab Injection

Recruiting
1
58
 
Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection
Peking University People's Hospital; Genor Biopharma Co. Ltd., company invest
Rheumatoid arthritis
 
 
NCT06799416: A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

Recruiting
1
32
Canada
ARGX-109, Placebo
argenx
Healthy Volunteer
07/25
07/25
pacibekitug (TOUR006) / Tourmaline Bio
TRANQUILITY, NCT06362759: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

Active, not recruiting
2
143
US
TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
Tourmaline Bio, Inc.
Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
03/25
12/25
spiriTED, NCT06088979: A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Recruiting
2
81
Europe, Canada, US, RoW
TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG
Tourmaline Bio, Inc.
Thyroid Eye Disease
11/25
11/26
reticulose (EOM613) / EOM Pharma
NCT05212532: A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

Recruiting
1
40
RoW
EOM613
EOM Pharmaceuticals
COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
02/22
03/22
clazakizumab (CSL300) / CSL Behring
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
ACTRN12624000567527: A Phase II Trial to Evaluate the Safety and Efficacy of clazakizumab for the desensitisation of highly sensitized patients on the deceased donor kidney transplant waiting list

Not yet recruiting
2
10
 
Royal Melbourne Hospital, John Perrett Bequest
End stage kidney disease
 
 
2020-002476-13: A study to look at the safety and success of using Clazakizumab in patients who have kidney disease and COVID-19.

Ongoing
2
20
Europe
Clazakizumab, N/A, Solution for injection/infusion, Clazakizumab
Imperial College London, Vitaeris Bio
Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen requirements or biochemical signs of hyperinflammation)., Patients with kidney disease or who are immunosuppressed, who also have a diagnosis of COVID19, which affects the lungs, requiring a hospital admission., Diseases [C] - Virus Diseases [C02]
 
 
NCT04494724: Clazakizumab vs. Placebo - COVID-19 Infection

Recruiting
2
60
US
Clazakizumab, Placebo
The Methodist Hospital System
COVID-19 Infection
12/20
07/21
NCT04363502: Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Recruiting
2
30
US
Clazakizumab, engineered humanized mAb directed against the human cytokine IL-6, Placebo
Johns Hopkins University
Covid19
05/22
05/22
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
02/25
03/25
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
NCT03380962: Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active, not recruiting
1/2
20
US
Clazakizumab, Anti-IL-6 monoclonal
Stanley Jordan, MD
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
08/25
08/25
NCT03380377: Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Completed
1/2
10
US
Clazakizumab
Stanley Jordan, MD
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
04/24
04/24
lenalidomide / Generic mfg.
ChiCTR-TTRCC-14004670: To study the Bioequivalence of following oral administration of domestic lenalidomide capsules in multiple myeloma patients

Recruiting
4
40
 
oral domestic produced lenalidomide capsule ;oral domestic produced lenalidomide capsule
West China Hospital; Level of the institution：, Self-financing
Multiple Myeloma
 
 
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie.

Ongoing
4
140
Europe
Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip)
St. Antonius Hospital, St. Antonius Hospital
multiple myeloma multipel myeloom
 
 
NCT00777881: Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Active, not recruiting
4
114
US
Lenalidomide, CC-5013, Revlimid, Dexamethasone
University of Pittsburgh
Multiple Myeloma
01/16
01/17
2012-001813-17: A study of the reaction of the vessels and cells of patients with myeloma getting chemotherapy.

Ongoing
4
110
Europe
Revlimid, Cyclophosphamide, Bortezomib, Thalidomide, Dexamethasone, PL 00032/0335, EU/1/04/274/001, EU/1/08/443/001, PL0065/5045R, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone
Hull and East Yorkshire Hospitals NHS Trust
Chemotherapy related thrombosis in patients treated for multiple myeloma.
 
 
ChiCTR-OIN-16008243: Clinical research of the efficacy and safety of Vitamin A acid combined with Rd scheme in multiple myeloma patients with the drug lenalidomide resistance,Single center, single arm, prospectie Ⅳ studies

Recruiting
4
15
 
Eligible patients into vitamin A acid joint Rd project group, all accept > 2 starting from the second cycle per cycle treatment curative effect evaluation of A cycle.Therapy for > = SD patients to disease progression
Beijing university people's hospital; Beijing university people's hospital, self funding
multiple myeloma
 
 
2017-004003-46: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Studio randomizzato, multicentrico, in aperto che compara due trattamenti standard, bortezomib-melfalan-prednisone (VMP) vs lenalidomide-desametasone (Rd) in pazienti non candidabili al trapianto affetti da mieloma multiplo (MM)

Not yet recruiting
4
350
Europe
Velcade, Melphalan, Prednisone, Lenalidomide 25 mg, Desametasone, [Velcade], [Melphalan], [Prednisone], [Lenalidomide 25 mg], [Desametasone], Powder for solution for injection, Film-coated tablet, Tablet, Capsule, hard, Oral drops, solution, VELCADE - 1 FLACONCINO DA 3.5 MG, ALKERAN - 2 MG COMPRESSE RIVESTITE CON FILM25 COMPRESSE, PREDNISONE TEVA - "5 MG COMPRESSE" 20 COMPRESSE IN BLISTER PVC-PVDC/ALU, REVLIMID - 25 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, SOLDESAM - 0.2% GOCCE ORALI, SOLUZIONE FLACONE 10 ML
DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO, AIFA - Italian Medicines Agency
Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant Pazienti con nuova diagnosi di MM = 65 anni o non eleggibili al trapianto autologo di cellule staminali, Newly diagnosed Multiple Myeloma patients with or older than 65 years or ineligible for autologousstem cell transplant Pazienti con nuova diagnosi di Mieloma Multiplo con et¿ superiore o uguale a 65 anni o non eleggibili al trapianto autologo di cellule staminali, Diseases [C] - Cancer [C04]
 
 
2019-002626-67: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOMIB, LENALIDOMIDA Y DEXAMETASONA EN PACIENTES CON MIELOMA MÚLTIPLE DE NUEVO DIAGNÓSTICO

Not yet recruiting
4
360
Europe
bortezomib, Revlimid, Dexamethasone, Revlimid, S02BA06, Powder and solution for solution for injection, Capsule, hard, Tablet, Velcade, Revlimid, Dexamethasone
Institut Català d'Oncologia, Institut Català d'Oncologia
Multiple myeloma Mieloma múltiple, Multiple myeloma mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900021558: Study for the efficacy and safety, the quality of life of patients and the occupational stress of doctors of RAD induction in the treatment of multiple myeloma.

Recruiting
4
60
 
lenalidomide ;bortezomib
The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Self-raised funds
multiple myeloma
 
 
ChiCTR1800020022: A multicenter, One-arm, Open, Prospective study for Low-dose Lenalidomide plus Rituximab (Laili) Regimen in the treatment of Elderly or Relapsed/Refractory B-cell non-Hodgkin's Lymphoma

Not yet recruiting
4
100
 
low dose of lenalidomide and rituximab
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, self-financed
B-cell non-Hodgkin's lymphoma
 
 
ChiCTR1900025376: Lenalidomide in Treatment-Refractory Lupus-Associated Skin Lesions in Systemic Lupus Erythematosus: A Single-Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Recruiting
4
30
 
lenalidomide 10mg qd ;placebo 10mg qd
Chinese Academy of Medical Sciences Peking Union Medical College Hospital; Chinese Academy of Medical Sciences Peking Union Medical College Hospital, National 13th Five-Year Key R&D Program Precision Medicine Project: Clinical and prognostic cohort study of systemic lupus erythematosus (2017YFC0907602)
systemic lupus erythematosus
 
 
ChiCTR1900022551: Waiting for ethics committee approval Induction therapy with bortezomib, lenalidomide, dexamethasone (VRD) in newly diagnosed multiple myeloma patients

Not yet recruiting
4
50
 
bortezomib/lenalidomide/dexamethasone (VRD)
Peking University People's Hospital; Peking University People's Hospital, CTTQ Pharmaceutical Group Co., Ltd.
multiple myeloma
 
 
ChiCTR2000030792: A multicenter, single-arm clinical study of bortezomib /lenalidomide /dexamethasone (VRD) regimen in newly diagnosed multiple myeloma patients

Recruiting
4
80
 
Bortezomib /lanaduramide /dexamethasone (VRD) regimen was induced in patients with newly diagnosed multiple myeloma
Center for Cancer Prevention and Treatment, Sun Yat-Sen University; Center for Cancer Prevention and Treatment, Sun Yat-Sen University, Provided by Zhengda Tianqing Pharmaceutical Group Co. Ltd. : bortezomib for injection, product name Qianping.
Multiple myeloma
 
 
ChiCTR1900026380: Rituximab plus Lenalidomide in elderly untreated patients with DLBCL

Recruiting
4
60
 
Rituximab plus Lenalidomide
Anhui Provincial Cance Hospital; Anhui Provincial Cance Hospital, Self-collected
DLBCL
 
 
ChiCTR2000039966: The efficacy of Bortezomib with lenalidomide and dexamethasone (VRd) in newly diagnosised multiple myeloma and screening for associated biomarkers

Recruiting
4
100
 
VRd regmen
Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, self-prepare capital
multiple myeloma
 
 
ChiCTR2000039485: A multicenter prospective clinical study of zanubrutinib combined with lenalidomide, temozolomide and CD20 mAb ± methotrexate in the treatment of primary / secondary central nervous system diffuse large B-cell lymphoma

Recruiting
4
40
 
high-dose MTX and zanubrutini + lenalidomide + temozolomide + CD20 mAb alternately ;zanubrutini + lenalidomide + temozolomide + CD20 mAb
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, BeiGene(Beijing) Co.,Ltd
central nervous system of Diffuse large B-cell lymphoma
 
 
ChiCTR2000040808: A multicenter, prospective clinical study Induction therapy with Domestic bortezomib /lenalidomide /dexamethasone (BLD) regimen in newly diagnosed multiple myeloma patients

Recruiting
4
100
 
bortezomib/lenalidomide/dexamethasone (BLD)
Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, Self-funded
Multiple Myeloma
 
 
NCT04217967: Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Completed
4
211
RoW
Ixazomib, Lenalidomide
Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Peking University First Hospital, Jilin Provincial Tumor Hospital, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Shanxi Medical University, Tianjin Medical University General Hospital, The First Affiliated Hospital of Anhui Medical University, Shanxi Bethune Hospital, Beijing Hospital
Multiple Myeloma
06/24
06/24
2021-000987-31: Impact of lenalidomide on immune cell expression in multiple myeloma Impact du lénalidomide sur l'expression des cellules immunitaires dans le myélome multiple

Not yet recruiting
4
22
Europe
Revlimid, Capsule, Revlimid
CHU Rennes, Celgene International II, sarl, French-speaking Myeloma Intergroup
Multiple Myeloma Myélome multiple, Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04]
 
 
2022-002253-26: International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab

Not yet recruiting
4
70
Europe, RoW
isatuximab, dexamethasone, lenalidomide, pomalidomide, Pomalidomide, SAR650984, Concentrate for solution for infusion, Tablet, Capsule, Capsule, hard, Dexamethason 4 mg JENAPHARM®, Dexamethason 8 mg JENAPHARM®, Revlimid® 5 mg, Revlimid® 10 mg, Revlimid® 15 mg, Revlimid® 20 mg, Revlimid® 25 mg, Imnovid® (Pomalidomide) 1 mg hard capsule, Imnovid® (Pomalidomide) 2 mg hard capsule, Imnovid® (Pomalidomide) 3 mg hard capsule, Imnovid® (Pomalidomide) 4 mg hard capsule, Zelvina® 5 mg, Zelvina® 10 mg, Zelvina® 15 mg, Zelvina® 20 mg, Zelvina® 25 mg, JAMP Pomalidomide 1 mg capsules, JAMP Pomalidomide 2 mg capsules, JAMP Pomalidomide 3 mg capsules, JAMP Pomalidomide 4 mg capsules
Sanofi-aventis recherche & développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-aventis recherche & développement, Sanofi-aventis recherche & developpement
Multiple myeloma, Multiple myloma (cancer), Diseases [C] - Cancer [C04]
 
 
NCT04842318: Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

Recruiting
4
789
RoW
BR for 6 cycles +R for 8 cycles, RCHOP for 6 cycles +R for 8 cycles, R2 for 6 cycles + R2 maintenance
Ruijin Hospital
Follicular Lymphoma
03/23
03/24
NCT03934684: Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
4
101
RoW
Drug: Carfilzomib + Dexamethasone, Kyprolis, Drug: Carfilzomib + Lenalidomide + Dexamethasone
Amgen
Relapsed Refractory Multiple Myeloma
03/23
06/25
ChiCTR2000035401: Lenalidomide in maintenance treatment of primary central nervous system lymphoma

Recruiting
4
30
 
Lenalidomide ;follow up
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, General project of Shanghai Health Committee
Primary CNS Lymphoma
 
 
ChiCTR1900025577: A prospective, non-randomized clinical study for bortezomib, lenadomide/cyclophosphamide and dexamethasone in the treatment of primary multiple myeloma

Completed
4
50
 
Bortezomib Combined with Dexamethasone and Lenalidomide ;Bortezomib combined with dexamethasone and cyclophosphamide
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Primary Health Care Foundation of China
Multiple Myeloma
 
 
ChiCTR2200062860: A single-arm, open, observational clinical study of selinexor combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed patients with extramedullary, plasma cell leukemia, or high-risk multiple myeloma

Recruiting
4
40
 
Selinexor+bortezomib+lenalidomide + dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, none
multiple myeloma
 
 
ChiCTR2000029863: A multicenter, prospective, randomized, study for Ixazomib plus Cyclophosphamide and Dexamethasone compared with Lenalidomide plus Cyclophosphamide and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma

Not yet recruiting
4
172
 
Ixazomib plus Cyclophosphamide and Dexamethasone ;Lenalidomide plus Cyclophosphamide and Dexamethasone
Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, raise independently
Multiple myeloma
 
 
Real MM, NCT03829371: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Recruiting
4
450
Europe
Velcade, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Daratumumab
University of Turin, Italy
Multiple Myeloma
01/27
01/30
ChiCTR2200056288: A multicenter, prospective, non-random cohort study of BR lenalidomide in the treatment of newly treated indolent B-cell lymphoma and elderly mantle cell lymphoma

Completed
4
60
 
lenalidomide vs. non lenalidomide treatment
Shandong Cancer Hospital; Shandong Cancer Hospital, self-financing
lymphoma
 
 
NCT05598580: Immunomodulators on HIV-1 Reservoir

Recruiting
4
48
RoW
Lenalidomide, Adenosylmethionine
First Affiliated Hospital of Zhejiang University
HIV Infections
05/24
11/24
NCT06409702: Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Recruiting
4
59
RoW
Carfilzomib, Kyprolis, Daratumumab, Darzalex, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy, Bortezomib(V), Lenalidomide(R), Dexamethasone(D)
The First Affiliated Hospital of Soochow University
Newly Diagnosed, High Risk, MRD, Multiple Myeloma
11/27
12/27
NCT05722405: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Recruiting
4
100
RoW
Ixazomib plus low-dose lenalidomide, Ixazomib
Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital
Multiple Myeloma
06/24
07/25
ChiCTR2100053520: Clinical study of lenalidomide maintenance after chemotherapy for intermediate and high-risk B-cell lymphoma

Recruiting
4
20
 
Oral maintenance therapy with lenalidomide
The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, Chinese Anti-Cancer Association Lymphoma Research Fund
B-cell lymphoma
 
 
HS-2883, NCT04989140: Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Recruiting
4
60
RoW
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Peking Union Medical College Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Tianjin Medical University General Hospital, The First Affiliated Hospital of Zhengzhou University, Peking University Third Hospital, Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, First Hospital of China Medical University
Multiple Myeloma
07/24
07/24
NCT06004765: Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS

Not yet recruiting
4
138
RoW
Lenalidomide, Azacitidine
Peking Union Medical College Hospital
Myelodysplastic Syndromes
08/24
08/25
ChiCTR2000035365: Lenalidomide for chemoradiotherapy prevention in advanced nasopharyngeal carcinoma patients: a randomized, double-blind, placebo-controlled trial

Not yet recruiting
4
200
 
Lenalidomide and chemoradiotherapy ;Placebo and chemoradiotherapy
Cancer Prevention and Treatment Center of Guigang People's Hospital; Cancer Prevention and Treatment Center of Guigang People's Hospital, no
nasopharyngeal carcinoma
 
 
ChiCTR2100048364: A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease

Not yet recruiting
4
20
 
Rituximab+lenalidomide
Department of Hematology, Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital, National Natural Science Foundation of China
Castleman disease
 
 
ChiCTR2200058237: A multicenter, real-world study of selinexor and VRD regimen in the treatment of newly diagnosed high-risk multiple myeloma

Not yet recruiting
4
35
 
Celinisol + bortezomib + lenalidomide + dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan
Multiple Myeloma
 
 
ChiCTR2000031516: A clinical study on the maintenance strategy of multiple myeloma after autologous hematopoietic stem cell transplantation based on the detection of minimal residual disease

Not yet recruiting
4
50
 
bortezomib/lenalidomide
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, research funding
multiple myeloma
 
 
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement

Not yet recruiting
4
20
 
None
The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation
diffuse large B-cell lymphoma with secondary CNS involvement
 
 
NCT07025005: Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

Not yet recruiting
4
44
RoW
Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone
Tanta University
Peripheral Neuropathy, Multiple Myeloma, Neoplasms
06/26
09/26
ChiCTR2100047227: Clinical study of autologous hematopoietic stem cell transplantation combined with daretozumab in the treatment of multiple myeloma

Recruiting
4
60
 
Granulocyte macrophage colony stimulating factor (gm-gsf) 300 was used on + 29, + 36, + 43, + 50 days after transplantation μ g. On + 30 days, + 37 days, + 44 days, + 51 days, 16 mg / kg daretozumab was infused for 4 times, and maintenance treatment was started on + 58 days ;Direct access to maintenance therapy Maintenance therapy: lenalidomide 25mg QD Before transplantation, 28 days, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months after transplantation, the physical fitness score, cellular immune function and disease remission were evaluated.
Sichuan Provicial People's Hospital; Sichuan Provicial People's Hospital, Research Foundation of Sichuan Provicial People's Hospital
multiple myeloma
 
 
ChiCTR2000038062: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy with bortezomib, lenalidomide and dexamethasone (BRd) in newly diagnosed elderly multiple myeloma

Recruiting
4
100
 
BRd+IRd+IR
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised
Multiple Myeloma
 
 
ChiCTR2000038075: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy of bortezomib, lenalidomide and dexamethasone (BRd) with newly diagnosed young multiple myeloma

Recruiting
4
150
 
BRd+/-ASCT+IRd+IR
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised
Multiple Myeloma
 
 
ChiCTR2500097978: The efficacy and safety of the D-base regimen (daratumumab+lenalidomide/pomalidomide) in the maintaining treatment after autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma patients

Not yet recruiting
4
40
 
Maintenance therapy with daratumumab+lenalidomide/pomalidomide after autologous transplantation
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Research Funds for West China Hospital of Sichuan University
Multiple Myeloma
 
 
ChiCTR2300078643: Efficacy and safety of IVPD regimen in patients with relapsed/refractory multiple myeloma resistant to bortezomib and/or lenalidomide: a multicenter, single-arm, prospective clinical study

Recruiting
4
67
 
Ixazomib; Venetoclax; Pomalidomide; Dexamethasone
The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, None
multiple myeloma
 
 
ChiCTR2300075660: A single-center, prospective, single-arm clinical study of daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma

Not yet recruiting
4
342
 
Bortezomib, doxorubicin, and dexamethasone (VAd) regimen induction chemotherapy for 2 cycles; daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation (ASCT)
Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, self-funded
Multiple myeloma
 
 
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Active, not recruiting
4
141
US
Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone
Takeda
Multiple Myeloma
11/26
11/26
ChiCTR2400079665: Single-arm clinical study of carfilazomib plus lenalidomide and dexamethasone regimen in patients with newly diagnosed multiple myeloma

Recruiting
4
36
 
Carfilzomib was combined with lenalidomide and dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, China Human Health Science and Technology Promotion Association
Multiple myeloma
 
 
ChiCTR2000034753: Lenalidomide for maintenance therapy in patients with diffuse large b-cell lymphoma at high risk of central recurrence: a prospective clinical study

Recruiting
4
100
 
Lenalidomide, 25 mg, orally, two weeks ;placebo
Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self financing
lymphoma
 
 
ACTRN12620000291987p: An ALLG Trial to compare the use of Selinexor, Lenalidomide and Dexamethasone with Lenalidomide alone for patients with newly diagnosed Multiple Myeloma undergoing Autologous stem cell transplant.

Not yet recruiting
3
232
 
Australian Leukeamia and Lymphoma Group (ALLG), Karyopharm Therapeutics, Inc
Multiple Myeloma
 
 
NCT00098475: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Active, not recruiting
3
452
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
11/08
10/25
NCT01093196 / 2008-008606-52: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Completed
3
660
Europe
Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide, dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma
11/12
07/24
CALGB-100104, NCT00114101: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Checkmark Data presentation from CALGB 100104 study for NDMM at ASCO
Jun 2017 - Jun 2017: Data presentation from CALGB 100104 study for NDMM at ASCO
Checkmark P3 data
May 2012 - May 2012: P3 data
Active, not recruiting
3
460
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Placebo Administration
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
12/12
02/26
NCT00602641: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
3
306
US, RoW
Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid
National Cancer Institute (NCI)
Multiple Myeloma
01/14
02/26
ACTRN12611000085976: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

Active, not recruiting
3
80
 
Australasian Leukaemia and Lymphoma Group, GELA, Australasian Leukaemia and Lymphoma Group, Celgene Global
Diffuse large B cell lymphoma (DLBCL) in elderly patients
 
 
ACTRN12612001045808: A Phase 3 open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (ALLG NHL27)

Completed
3
1000
 
The Lymphoma academic research organisation, Australasian Leukaemia and Lymphoma Group
follicular lymphoma
 
 
2005-001554-24: INTERET D’UN TRAITEMENT D’ENTRETIEN PAR REVLIMID APRES AUTOGREFFE DE CELLULES SOUCHES CHEZ LES PATIENTS DE MOINS DE 65 ANS ATTEINTS DE MYELOME(Essai de phase III, multicentrique, randomisé, double aveugle, versus placebo)

Ongoing
3
40
Europe
Revlimid Lenalidomide, CC-5013, REVLIMID (LENALIDOMIDE), REVLIMID (LENALIDOMIDE)
CHU de TOULOUSE
Myélome de novo stade DS : III, II, I with one symptomatic bone ogique) No sign of cardia insufficiency and echography must schow FEV> 40 %. no hepatic insufficiency : bilirubine< 35µmol/L and SGOT,SGPT, alkaline phosphatases lower than 4 N. No respiratory insufficiency : DLCO >50 % N. no previous kidney insufficiencey non related to the disease and defined bycréatinine >160 µmol/L. Sérology HIV- Myélome de novo De stade DS : III, II, I avec 1 lésion osseuse symptomatique (radiologique) Pas de signes cliniques d\'insuffisance cardiaque ou coronarienne et au plan échographique FEV> 40 %. Pas d’atteinte hépatique : bilirubine< 35µmol/L et des SGOT, des SGPT, des phosphatases alcalines inférieures à 4 N. Pas d’atteinte respiratoire : tests ventilatoires et DLCO >50 % N. Pas d’atteinte rénale antérieure non liée à la maladie et définie par une créatinine >160 µmol/L. Sérologie HIV-
 
 
2007-004007-34: Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide Een gerandomiseerde fase III studie bij niet eerder voorbehandelde patienten met Multipel Myeloom, die niet in aanmerking komen voor hoge dosis chemotherapie, naar het effect van Melfalan Prednison en Thalidomide, gevolgd door onderhoudsbehandeling met Thalidomide versus Melfalan Prednison en Lenalidomide, gevolgd door onderhoudsbehandeling met Lenalidomide.

Ongoing
3
500
Europe
Revlimid, Thalidomide Celgene, Revlimid, Thalidomide Celgene
HOVON Foundation, Dutch Cancer Society, Celgene,
Multiple Myeloma
 
 
2007-003945-33: A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Randomisierter Vergleich von 25 mg versus 5 mg Lenalidomid als Erhaltungstherapie nach Hochdosistherapie und autologer Blutstammzelltransplantation bei Patienten mit Multiplen Myelom

Ongoing
3
194
Europe
Revlimid (5 mg), Revlimid (10mg), Revlimid (25mg), Revlimid (5 mg), Revlimid (10mg), Revlimid (25mg)
Gesellschaft für Medizinische Innovation –Hämatologie und Onkologie mbH (GMIHO), Fa. Celgene
Patients with multiple myeloma Multiples Myelom
 
 
2008-004083-39: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma

Ongoing
3
348
Europe
Dexamethasone, Melphalan, d, Mel, Revlimid, Revlimid
GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
primary treatment of multiple myeloma patients of age 60 till 75 years
 
 
2009-016871-32: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Ongoing
3
700
Europe
REVLIMID (LENALIDOMODE), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB)
CHU de TOULOUSE, , PHRC National/Ministère de la Santé, Celgene International SARL, Janssen Pharmaceutica NV, Amgen
Myeloma, Multiple Myeloma
 
 
2010-019173-16: Randomisierte Phase III Studie für Patienten mit Multiplem Myelom zur Untersuchung zweier Therapieschemata einer Bortezomib-basierten Induktionsthearpie und einer Lenalidomid-Konsolidierungstherapie gefolgt von einer Erhaltungstherapie mit Lenalidomid

Ongoing
3
604
Europe
Lenalidomide, CC-5013, Velcade, Revlimid, Velcade, Revlimid
University Hospital Heidelberg, Fa. Janssen-Cilag GmbH, Neuss, Fa. Celgene, München, Fa. Chugai, Frankfurt am Main, The Binding Site, Schwetzingen
multiple myeloma (symptomatic, newly diagnosed)
 
 
2009-013856-61: Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/Dexamethason versus Lenalidomid/Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiviertem Multiplen Myelom

Ongoing
3
282
Europe
autologous PBSC, CD34+ cells, Revlimid®, Revlimid®
University Hospital Heidelberg, Amgen, Celgene, Chugai, Hopp-Foundation
Multiple Myeloma (1.-3. Progression/Relapse)
 
 
2010-021557-40: A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE III DI CONFRONTO TRA BORTEZOMIB, CICLOFOSFAMIDE E DESAMETASONE RISPETTO A LENALIDOMIDE, CICLOFOSFAMIDE E DESAMETASONE IN PAZIENTI CON MIELOMA MULTIPLO IN PRIMA RICADUTA.

Ongoing
3
200
Europe
VELCADE, SOLDESAM, ENDOXAN BAXTER*INIET 1FL 500MG, REVLIMID*21CPS 15MG, REVLIMID*21CPS 10MG, REVLIMID*21CPS 5MG, VELCADE, SOLDESAM, ENDOXAN BAXTER*INIET 1FL 500MG, REVLIMID*21CPS 15MG, REVLIMID*21CPS 10MG, REVLIMID*21CPS 5MG
ISTITUTO NAZIONALE PER LA CURA TUMORI, ministero della salute
Multiple mieloma Mieloma multiplo
 
 
2014-003079-40: Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment Studie für Patienten mit zuvor unbehandeltem Multiplem Myelom zur Untersuchung der Wirksamkeit von Elotuzumab im Rahmen einer Induktions- und Konsolidierungstherapie mit Bortezomib/Lenalidomid/Dexamethason sowie in der Erhaltungstherapie mit Lenalidomid

Ongoing
3
516
Europe
Lenalidomide, Elotuzumab, CC-5013, BMS-901608, formerly known as HuLuc63, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg, Celgene International Sarl, Bristol-Myers Squibb International Corporation
Newly diagnosed symptomatic multiple myeloma symptomatisches Multiples Myelom, Primärtherapie
 
 
POLLUX, NCT02076009 / 2013-005525-23: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Checkmark Four-year follow up data from trial for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Four-year follow up data from trial for multiple myeloma at ASH 2019
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018
More
Completed
3
569
Europe, Canada, Japan, US, RoW
Daratumumab, Lenalidomide, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
03/16
11/24
SWOG S0777, NCT00644228: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Checkmark From SWOG 0777 trial at ASH 2015
Dec 2015 - Dec 2015: From SWOG 0777 trial at ASH 2015
Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Active, not recruiting
3
525
US, RoW
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
11/15
09/25
NCT01685814 / 2009-016616-21: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Active, not recruiting
3
406
Europe
Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Celgene Corporation
Previously Untreated Symptomatic Multiple Myeloma
09/16
12/23
2015-002380-42: Research study to determine whether a combination of 3 drugs calledlenalidomide, carfilzomib and dexamethasone given to persons afterautologous stem cell (a young cell without a specific purpose from whichother cell types develop) transplant is better than lenalidomidemaintenance alone. Badanie Kliniczne prowadzone celem ustalenia czy kombinacja trzechleków o nazwie lenalidomid, carfilzomib i dexametazon podana osobom poautologicznej transplantacji komórek macierzystych (pierwotne,niewyspecjalizowane komórki nie posiadające określonego przeznaczenia,które mają zdolność do przekształcania się w wyspecjalizowane komórki)jest skuteczniejsza niż podawanie samego leku lenalidomid.

Ongoing
3
180
Europe
Dexamethasone, Capsule, hard, Powder for solution for infusion, Tablet, Revlimid, Kyprolis
Polish Myeloma Consortium, University of Chicago, Celgene Europe Ltd
Multiple Myeloma Szpiczak Mnogi, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała)., Diseases [C] - Cancer [C04]
 
 
2016-004010-10: A Phase 3 evaluation of how PET scans can help guide further therapy or no therapy for patients with previously untreated, high tumour burden follicular lymphoma

Ongoing
3
840
Europe
Rituximab (for intravenous infusion), Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg), Concentrate for solution for infusion, Capsule, hard, Solution for injection, Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg)
University of Liverpool, Cancer Research UK
Previously untreated, high tumour burden follicular lymphoma, Follicular lymphoma is a cancer of the immune system. The cancerous cells accumulate mainly in lymph glands which become swollen. It is incurable and therefore requirement multiple lines of treatment., Diseases [C] - Cancer [C04]
 
 
NCT02257515: Stem Cell Transplant and Lenalidomide With and Without Bortezomib in Treating Patients With Multiple Myeloma

Active, not recruiting
3
750
US
lenalidomide, CC-5013, IMiD-1, Revlimid, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, bortezomib, LDP 341, MLN341, VELCADE, quality-of-life assessment, quality of life assessment, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, autologous-autologous tandem hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
12/17
 
2017-002290-19: Rituximab maintenance will be compared to “lenalidomide plus rituximab maintenance followed by lenalidomide only maintenance” for relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Not yet recruiting
3
450
Europe
Capsule, hard, Concentrate for solution for infusion, Revlimid 2.5mg, hard capsules, Revlimid 5mg, hard capsules, Revlimid 10mg, hard capsules, Revlimid 15mg, hard capsules, Revlimid 20.0 mg, hard capsules, MabThera 500mg, concentrate for solution for infusion
Celgene Corporation, Celgene Corporation
relapsed/refractory follicular, marginal zone or mantle cell lymphoma, Three types of blood cancer called lymphoma, Diseases [C] - Cancer [C04]
 
 
MAIA, NCT02252172 / 2014-002273-11: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Checkmark Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Checkmark From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Jun 2021 - Jun 2021: From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Checkmark Data from trial in combination with Revlimid for multiple myeloma at ASH 2020
More
Completed
3
737
Europe, Canada, US, RoW
Daratumumab IV, JNJ-54767414, Lenalidomide, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
09/18
10/24
2018-004330-15: A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma Étude de phase III randomisée, multicentrique, comparant l’administration continue ou pour une durée fixe de l’association daratumumab, lenalidomide et dexaméthasone dans le myélome multiple en rechute

Not yet recruiting
3
434
Europe
Daratumumab, Lenalidomide, Dexamethasone, Solution for infusion, Capsule, hard, , DARZALEX, REVLIMID
Assistance Publique - Hôpitaux de Paris (AP-HP), Inca
multiple myeloma myelome multiple, myeloma myelome, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01169337: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Checkmark ECOG E3A06 study
Oct 2018 - Oct 2018: ECOG E3A06 study
Active, not recruiting
3
226
Europe, US
Clinical Observation, observation, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Light Chain Deposition Disease, Smoldering Multiple Myeloma
01/19
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rizaben (tranilast) / Kissei, Nuon Therapeutics
ChiCTR2000030002: Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
4
60
China
conventional therapy ;conventional therapy and Tranilast
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Anhui Development and Reform Commission
Novel Coronavirus Pneumonia (COVID-19)
 
 
NCT05130892: Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI

Completed
4
132
RoW
Colchicine, Tranilast, Oridonin
Wuhan Union Hospital, China
NLRP3, hsCRP, Percutaneous Coronary Intervention
02/23
02/23
NCT06307288: Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea

Enrolling by invitation
4
45
RoW
minocycline, tranilast
Second Affiliated Hospital of Xi'an Jiaotong University
Rosacea
06/24
06/24
NCT03923140: A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Recruiting
2
71
RoW
Tranilast, Rizaben
Peking Union Medical College Hospital
Cryopyrin-Associated Periodic Syndromes
04/24
10/24
NCT05626829: Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Recruiting
2
18
RoW
Tranilast
Jian Guan
Nasopharyngeal Carcinoma, Recurrent Cancer
07/24
11/24
TAPES, NCT06643689: Tranilast Vs. Steroids to Prevent Esophageal Stricture () After Endoscopic Resection for Superficial Neoplasms

Not yet recruiting
2
394
RoW
Tranilast, Dexamethasone
Second Affiliated Hospital, School of Medicine, Zhejiang University, The Third People's Hospital of Hangzhou, Xiangya Hospital of Central South University
Esophageal Stricture, Esophageal Neoplasms
12/27
12/28
ChiCTR1800015808: Pilot Clinical Study of Chemo-Cocktail (TTF) for Recurrent Glioblastoma

Recruiting
1
10
 
temmozoldmide+tranilast+fasudil
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, No
Recurrent Glioblastoma
 
 
NCT03490708: A Clinical Study of Tranilast in the Treatment of Mucinoses

Not yet recruiting
1
56
NA
Tranilast
The First Affiliated Hospital with Nanjing Medical University
Mucinoses
06/22
12/22
NCT06689514: Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia

Not yet recruiting
1
30
RoW
alpha receptor antagonist, Low dose Tranilast, High dose Tranilast
Yifeng Jing
Prostatic Hypertrophy, Benign
12/25
12/25
ChiCTR1900028455: A single center, randomized, single blind, controlled trial for tranilast in the treatment of gout

Not yet recruiting
N/A
160
 
take one tranilast capsule (each containing 0.1g of tranilast), three times a day, take it after three meals, treatment for one week ;take 2 capsules of tranilast (0.1g of tranilast per capsule), 3 times / day, after three meals, treatment for 1 week ;Take 1 diclofenac capsule (each containing 50mg of diclofenac) twice a day, take it after breakfast and dinner, and treat for 1 week ;Take 1 colchicine tablet (each tablet contains 0.5mg colchicine), 3 times / day, take after three meals, treatment for 1 week
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital), Researchers spontaneous
Gout
 
 
gerilimzumab (ARGX-109) / argenx
ACTRN12615001141538: The second healthy volunteer study assessing the safety, tolerability, and pharmacokinetics (blood levels) of gerilimzumab against placebo.

Active, not recruiting
1
18
 
Clinical Network Services Pty Ltd, RuiYi Inc
Rheumatoid Arthritis
 
 
ChiCTR-IIR-17013205: A Pharmacokinetics Study of Gerilimzumab Injection

Recruiting
1
58
 
Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection ;Subcutaneous injection
Peking University People's Hospital; Genor Biopharma Co. Ltd., company invest
Rheumatoid arthritis
 
 
NCT06799416: A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

Recruiting
1
32
Canada
ARGX-109, Placebo
argenx
Healthy Volunteer
07/25
07/25
pacibekitug (TOUR006) / Tourmaline Bio
TRANQUILITY, NCT06362759: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

Active, not recruiting
2
143
US
TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
Tourmaline Bio, Inc.
Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
03/25
12/25
spiriTED, NCT06088979: A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Recruiting
2
81
Europe, Canada, US, RoW
TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG
Tourmaline Bio, Inc.
Thyroid Eye Disease
11/25
11/26
reticulose (EOM613) / EOM Pharma
NCT05212532: A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

Recruiting
1
40
RoW
EOM613
EOM Pharmaceuticals
COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
02/22
03/22
clazakizumab (CSL300) / CSL Behring
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Recruiting
2/3
2310
Europe, Canada, Japan, US, RoW
CSL300, Clazakizumab, Placebo
CSL Behring
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
08/29
08/29
ACTRN12624000567527: A Phase II Trial to Evaluate the Safety and Efficacy of clazakizumab for the desensitisation of highly sensitized patients on the deceased donor kidney transplant waiting list

Not yet recruiting
2
10
 
Royal Melbourne Hospital, John Perrett Bequest
End stage kidney disease
 
 
2020-002476-13: A study to look at the safety and success of using Clazakizumab in patients who have kidney disease and COVID-19.

Ongoing
2
20
Europe
Clazakizumab, N/A, Solution for injection/infusion, Clazakizumab
Imperial College London, Vitaeris Bio
Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen requirements or biochemical signs of hyperinflammation)., Patients with kidney disease or who are immunosuppressed, who also have a diagnosis of COVID19, which affects the lungs, requiring a hospital admission., Diseases [C] - Virus Diseases [C02]
 
 
NCT04494724: Clazakizumab vs. Placebo - COVID-19 Infection

Recruiting
2
60
US
Clazakizumab, Placebo
The Methodist Hospital System
COVID-19 Infection
12/20
07/21
NCT04363502: Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Recruiting
2
30
US
Clazakizumab, engineered humanized mAb directed against the human cytokine IL-6, Placebo
Johns Hopkins University
Covid19
05/22
05/22
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
02/25
03/25
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
NCT03380962: Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active, not recruiting
1/2
20
US
Clazakizumab, Anti-IL-6 monoclonal
Stanley Jordan, MD
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
08/25
08/25
NCT03380377: Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Completed
1/2
10
US
Clazakizumab
Stanley Jordan, MD
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
04/24
04/24
lenalidomide / Generic mfg.
ChiCTR-TTRCC-14004670: To study the Bioequivalence of following oral administration of domestic lenalidomide capsules in multiple myeloma patients

Recruiting
4
40
 
oral domestic produced lenalidomide capsule ;oral domestic produced lenalidomide capsule
West China Hospital; Level of the institution：, Self-financing
Multiple Myeloma
 
 
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie.

Ongoing
4
140
Europe
Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip)
St. Antonius Hospital, St. Antonius Hospital
multiple myeloma multipel myeloom
 
 
NCT00777881: Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Active, not recruiting
4
114
US
Lenalidomide, CC-5013, Revlimid, Dexamethasone
University of Pittsburgh
Multiple Myeloma
01/16
01/17
2012-001813-17: A study of the reaction of the vessels and cells of patients with myeloma getting chemotherapy.

Ongoing
4
110
Europe
Revlimid, Cyclophosphamide, Bortezomib, Thalidomide, Dexamethasone, PL 00032/0335, EU/1/04/274/001, EU/1/08/443/001, PL0065/5045R, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone
Hull and East Yorkshire Hospitals NHS Trust
Chemotherapy related thrombosis in patients treated for multiple myeloma.
 
 
ChiCTR-OIN-16008243: Clinical research of the efficacy and safety of Vitamin A acid combined with Rd scheme in multiple myeloma patients with the drug lenalidomide resistance,Single center, single arm, prospectie Ⅳ studies

Recruiting
4
15
 
Eligible patients into vitamin A acid joint Rd project group, all accept > 2 starting from the second cycle per cycle treatment curative effect evaluation of A cycle.Therapy for > = SD patients to disease progression
Beijing university people's hospital; Beijing university people's hospital, self funding
multiple myeloma
 
 
2017-004003-46: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Studio randomizzato, multicentrico, in aperto che compara due trattamenti standard, bortezomib-melfalan-prednisone (VMP) vs lenalidomide-desametasone (Rd) in pazienti non candidabili al trapianto affetti da mieloma multiplo (MM)

Not yet recruiting
4
350
Europe
Velcade, Melphalan, Prednisone, Lenalidomide 25 mg, Desametasone, [Velcade], [Melphalan], [Prednisone], [Lenalidomide 25 mg], [Desametasone], Powder for solution for injection, Film-coated tablet, Tablet, Capsule, hard, Oral drops, solution, VELCADE - 1 FLACONCINO DA 3.5 MG, ALKERAN - 2 MG COMPRESSE RIVESTITE CON FILM25 COMPRESSE, PREDNISONE TEVA - "5 MG COMPRESSE" 20 COMPRESSE IN BLISTER PVC-PVDC/ALU, REVLIMID - 25 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, SOLDESAM - 0.2% GOCCE ORALI, SOLUZIONE FLACONE 10 ML
DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO, AIFA - Italian Medicines Agency
Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant Pazienti con nuova diagnosi di MM = 65 anni o non eleggibili al trapianto autologo di cellule staminali, Newly diagnosed Multiple Myeloma patients with or older than 65 years or ineligible for autologousstem cell transplant Pazienti con nuova diagnosi di Mieloma Multiplo con et¿ superiore o uguale a 65 anni o non eleggibili al trapianto autologo di cellule staminali, Diseases [C] - Cancer [C04]
 
 
2019-002626-67: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOMIB, LENALIDOMIDA Y DEXAMETASONA EN PACIENTES CON MIELOMA MÚLTIPLE DE NUEVO DIAGNÓSTICO

Not yet recruiting
4
360
Europe
bortezomib, Revlimid, Dexamethasone, Revlimid, S02BA06, Powder and solution for solution for injection, Capsule, hard, Tablet, Velcade, Revlimid, Dexamethasone
Institut Català d'Oncologia, Institut Català d'Oncologia
Multiple myeloma Mieloma múltiple, Multiple myeloma mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900021558: Study for the efficacy and safety, the quality of life of patients and the occupational stress of doctors of RAD induction in the treatment of multiple myeloma.

Recruiting
4
60
 
lenalidomide ;bortezomib
The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Self-raised funds
multiple myeloma
 
 
ChiCTR1800020022: A multicenter, One-arm, Open, Prospective study for Low-dose Lenalidomide plus Rituximab (Laili) Regimen in the treatment of Elderly or Relapsed/Refractory B-cell non-Hodgkin's Lymphoma

Not yet recruiting
4
100
 
low dose of lenalidomide and rituximab
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, self-financed
B-cell non-Hodgkin's lymphoma
 
 
ChiCTR1900025376: Lenalidomide in Treatment-Refractory Lupus-Associated Skin Lesions in Systemic Lupus Erythematosus: A Single-Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Recruiting
4
30
 
lenalidomide 10mg qd ;placebo 10mg qd
Chinese Academy of Medical Sciences Peking Union Medical College Hospital; Chinese Academy of Medical Sciences Peking Union Medical College Hospital, National 13th Five-Year Key R&D Program Precision Medicine Project: Clinical and prognostic cohort study of systemic lupus erythematosus (2017YFC0907602)
systemic lupus erythematosus
 
 
ChiCTR1900022551: Waiting for ethics committee approval Induction therapy with bortezomib, lenalidomide, dexamethasone (VRD) in newly diagnosed multiple myeloma patients

Not yet recruiting
4
50
 
bortezomib/lenalidomide/dexamethasone (VRD)
Peking University People's Hospital; Peking University People's Hospital, CTTQ Pharmaceutical Group Co., Ltd.
multiple myeloma
 
 
ChiCTR2000030792: A multicenter, single-arm clinical study of bortezomib /lenalidomide /dexamethasone (VRD) regimen in newly diagnosed multiple myeloma patients

Recruiting
4
80
 
Bortezomib /lanaduramide /dexamethasone (VRD) regimen was induced in patients with newly diagnosed multiple myeloma
Center for Cancer Prevention and Treatment, Sun Yat-Sen University; Center for Cancer Prevention and Treatment, Sun Yat-Sen University, Provided by Zhengda Tianqing Pharmaceutical Group Co. Ltd. : bortezomib for injection, product name Qianping.
Multiple myeloma
 
 
ChiCTR1900026380: Rituximab plus Lenalidomide in elderly untreated patients with DLBCL

Recruiting
4
60
 
Rituximab plus Lenalidomide
Anhui Provincial Cance Hospital; Anhui Provincial Cance Hospital, Self-collected
DLBCL
 
 
ChiCTR2000039966: The efficacy of Bortezomib with lenalidomide and dexamethasone (VRd) in newly diagnosised multiple myeloma and screening for associated biomarkers

Recruiting
4
100
 
VRd regmen
Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, self-prepare capital
multiple myeloma
 
 
ChiCTR2000039485: A multicenter prospective clinical study of zanubrutinib combined with lenalidomide, temozolomide and CD20 mAb ± methotrexate in the treatment of primary / secondary central nervous system diffuse large B-cell lymphoma

Recruiting
4
40
 
high-dose MTX and zanubrutini + lenalidomide + temozolomide + CD20 mAb alternately ;zanubrutini + lenalidomide + temozolomide + CD20 mAb
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, BeiGene(Beijing) Co.,Ltd
central nervous system of Diffuse large B-cell lymphoma
 
 
ChiCTR2000040808: A multicenter, prospective clinical study Induction therapy with Domestic bortezomib /lenalidomide /dexamethasone (BLD) regimen in newly diagnosed multiple myeloma patients

Recruiting
4
100
 
bortezomib/lenalidomide/dexamethasone (BLD)
Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, Self-funded
Multiple Myeloma
 
 
NCT04217967: Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Completed
4
211
RoW
Ixazomib, Lenalidomide
Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Peking University First Hospital, Jilin Provincial Tumor Hospital, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Shanxi Medical University, Tianjin Medical University General Hospital, The First Affiliated Hospital of Anhui Medical University, Shanxi Bethune Hospital, Beijing Hospital
Multiple Myeloma
06/24
06/24
2021-000987-31: Impact of lenalidomide on immune cell expression in multiple myeloma Impact du lénalidomide sur l'expression des cellules immunitaires dans le myélome multiple

Not yet recruiting
4
22
Europe
Revlimid, Capsule, Revlimid
CHU Rennes, Celgene International II, sarl, French-speaking Myeloma Intergroup
Multiple Myeloma Myélome multiple, Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04]
 
 
2022-002253-26: International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab

Not yet recruiting
4
70
Europe, RoW
isatuximab, dexamethasone, lenalidomide, pomalidomide, Pomalidomide, SAR650984, Concentrate for solution for infusion, Tablet, Capsule, Capsule, hard, Dexamethason 4 mg JENAPHARM®, Dexamethason 8 mg JENAPHARM®, Revlimid® 5 mg, Revlimid® 10 mg, Revlimid® 15 mg, Revlimid® 20 mg, Revlimid® 25 mg, Imnovid® (Pomalidomide) 1 mg hard capsule, Imnovid® (Pomalidomide) 2 mg hard capsule, Imnovid® (Pomalidomide) 3 mg hard capsule, Imnovid® (Pomalidomide) 4 mg hard capsule, Zelvina® 5 mg, Zelvina® 10 mg, Zelvina® 15 mg, Zelvina® 20 mg, Zelvina® 25 mg, JAMP Pomalidomide 1 mg capsules, JAMP Pomalidomide 2 mg capsules, JAMP Pomalidomide 3 mg capsules, JAMP Pomalidomide 4 mg capsules
Sanofi-aventis recherche & développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-aventis recherche & développement, Sanofi-aventis recherche & developpement
Multiple myeloma, Multiple myloma (cancer), Diseases [C] - Cancer [C04]
 
 
NCT04842318: Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

Recruiting
4
789
RoW
BR for 6 cycles +R for 8 cycles, RCHOP for 6 cycles +R for 8 cycles, R2 for 6 cycles + R2 maintenance
Ruijin Hospital
Follicular Lymphoma
03/23
03/24
NCT03934684: Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
4
101
RoW
Drug: Carfilzomib + Dexamethasone, Kyprolis, Drug: Carfilzomib + Lenalidomide + Dexamethasone
Amgen
Relapsed Refractory Multiple Myeloma
03/23
06/25
ChiCTR2000035401: Lenalidomide in maintenance treatment of primary central nervous system lymphoma

Recruiting
4
30
 
Lenalidomide ;follow up
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, General project of Shanghai Health Committee
Primary CNS Lymphoma
 
 
ChiCTR1900025577: A prospective, non-randomized clinical study for bortezomib, lenadomide/cyclophosphamide and dexamethasone in the treatment of primary multiple myeloma

Completed
4
50
 
Bortezomib Combined with Dexamethasone and Lenalidomide ;Bortezomib combined with dexamethasone and cyclophosphamide
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Primary Health Care Foundation of China
Multiple Myeloma
 
 
ChiCTR2200062860: A single-arm, open, observational clinical study of selinexor combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed patients with extramedullary, plasma cell leukemia, or high-risk multiple myeloma

Recruiting
4
40
 
Selinexor+bortezomib+lenalidomide + dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, none
multiple myeloma
 
 
ChiCTR2000029863: A multicenter, prospective, randomized, study for Ixazomib plus Cyclophosphamide and Dexamethasone compared with Lenalidomide plus Cyclophosphamide and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma

Not yet recruiting
4
172
 
Ixazomib plus Cyclophosphamide and Dexamethasone ;Lenalidomide plus Cyclophosphamide and Dexamethasone
Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, raise independently
Multiple myeloma
 
 
Real MM, NCT03829371: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Recruiting
4
450
Europe
Velcade, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Daratumumab
University of Turin, Italy
Multiple Myeloma
01/27
01/30
ChiCTR2200056288: A multicenter, prospective, non-random cohort study of BR lenalidomide in the treatment of newly treated indolent B-cell lymphoma and elderly mantle cell lymphoma

Completed
4
60
 
lenalidomide vs. non lenalidomide treatment
Shandong Cancer Hospital; Shandong Cancer Hospital, self-financing
lymphoma
 
 
NCT05598580: Immunomodulators on HIV-1 Reservoir

Recruiting
4
48
RoW
Lenalidomide, Adenosylmethionine
First Affiliated Hospital of Zhejiang University
HIV Infections
05/24
11/24
NCT06409702: Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Recruiting
4
59
RoW
Carfilzomib, Kyprolis, Daratumumab, Darzalex, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy, Bortezomib(V), Lenalidomide(R), Dexamethasone(D)
The First Affiliated Hospital of Soochow University
Newly Diagnosed, High Risk, MRD, Multiple Myeloma
11/27
12/27
NCT05722405: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Recruiting
4
100
RoW
Ixazomib plus low-dose lenalidomide, Ixazomib
Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital
Multiple Myeloma
06/24
07/25
ChiCTR2100053520: Clinical study of lenalidomide maintenance after chemotherapy for intermediate and high-risk B-cell lymphoma

Recruiting
4
20
 
Oral maintenance therapy with lenalidomide
The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, Chinese Anti-Cancer Association Lymphoma Research Fund
B-cell lymphoma
 
 
HS-2883, NCT04989140: Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Recruiting
4
60
RoW
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Peking Union Medical College Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Tianjin Medical University General Hospital, The First Affiliated Hospital of Zhengzhou University, Peking University Third Hospital, Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, First Hospital of China Medical University
Multiple Myeloma
07/24
07/24
NCT06004765: Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS

Not yet recruiting
4
138
RoW
Lenalidomide, Azacitidine
Peking Union Medical College Hospital
Myelodysplastic Syndromes
08/24
08/25
ChiCTR2000035365: Lenalidomide for chemoradiotherapy prevention in advanced nasopharyngeal carcinoma patients: a randomized, double-blind, placebo-controlled trial

Not yet recruiting
4
200
 
Lenalidomide and chemoradiotherapy ;Placebo and chemoradiotherapy
Cancer Prevention and Treatment Center of Guigang People's Hospital; Cancer Prevention and Treatment Center of Guigang People's Hospital, no
nasopharyngeal carcinoma
 
 
ChiCTR2100048364: A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease

Not yet recruiting
4
20
 
Rituximab+lenalidomide
Department of Hematology, Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital, National Natural Science Foundation of China
Castleman disease
 
 
ChiCTR2200058237: A multicenter, real-world study of selinexor and VRD regimen in the treatment of newly diagnosed high-risk multiple myeloma

Not yet recruiting
4
35
 
Celinisol + bortezomib + lenalidomide + dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan
Multiple Myeloma
 
 
ChiCTR2000031516: A clinical study on the maintenance strategy of multiple myeloma after autologous hematopoietic stem cell transplantation based on the detection of minimal residual disease

Not yet recruiting
4
50
 
bortezomib/lenalidomide
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, research funding
multiple myeloma
 
 
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement

Not yet recruiting
4
20
 
None
The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation
diffuse large B-cell lymphoma with secondary CNS involvement
 
 
NCT07025005: Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

Not yet recruiting
4
44
RoW
Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone
Tanta University
Peripheral Neuropathy, Multiple Myeloma, Neoplasms
06/26
09/26
ChiCTR2100047227: Clinical study of autologous hematopoietic stem cell transplantation combined with daretozumab in the treatment of multiple myeloma

Recruiting
4
60
 
Granulocyte macrophage colony stimulating factor (gm-gsf) 300 was used on + 29, + 36, + 43, + 50 days after transplantation μ g. On + 30 days, + 37 days, + 44 days, + 51 days, 16 mg / kg daretozumab was infused for 4 times, and maintenance treatment was started on + 58 days ;Direct access to maintenance therapy Maintenance therapy: lenalidomide 25mg QD Before transplantation, 28 days, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months after transplantation, the physical fitness score, cellular immune function and disease remission were evaluated.
Sichuan Provicial People's Hospital; Sichuan Provicial People's Hospital, Research Foundation of Sichuan Provicial People's Hospital
multiple myeloma
 
 
ChiCTR2000038062: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy with bortezomib, lenalidomide and dexamethasone (BRd) in newly diagnosed elderly multiple myeloma

Recruiting
4
100
 
BRd+IRd+IR
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised
Multiple Myeloma
 
 
ChiCTR2000038075: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy of bortezomib, lenalidomide and dexamethasone (BRd) with newly diagnosed young multiple myeloma

Recruiting
4
150
 
BRd+/-ASCT+IRd+IR
The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised
Multiple Myeloma
 
 
ChiCTR2500097978: The efficacy and safety of the D-base regimen (daratumumab+lenalidomide/pomalidomide) in the maintaining treatment after autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma patients

Not yet recruiting
4
40
 
Maintenance therapy with daratumumab+lenalidomide/pomalidomide after autologous transplantation
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Research Funds for West China Hospital of Sichuan University
Multiple Myeloma
 
 
ChiCTR2300078643: Efficacy and safety of IVPD regimen in patients with relapsed/refractory multiple myeloma resistant to bortezomib and/or lenalidomide: a multicenter, single-arm, prospective clinical study

Recruiting
4
67
 
Ixazomib; Venetoclax; Pomalidomide; Dexamethasone
The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, None
multiple myeloma
 
 
ChiCTR2300075660: A single-center, prospective, single-arm clinical study of daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma

Not yet recruiting
4
342
 
Bortezomib, doxorubicin, and dexamethasone (VAd) regimen induction chemotherapy for 2 cycles; daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation (ASCT)
Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, self-funded
Multiple myeloma
 
 
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Active, not recruiting
4
141
US
Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone
Takeda
Multiple Myeloma
11/26
11/26
ChiCTR2400079665: Single-arm clinical study of carfilazomib plus lenalidomide and dexamethasone regimen in patients with newly diagnosed multiple myeloma

Recruiting
4
36
 
Carfilzomib was combined with lenalidomide and dexamethasone
Qingdao Municipal Hospital; Qingdao Municipal Hospital, China Human Health Science and Technology Promotion Association
Multiple myeloma
 
 
ChiCTR2000034753: Lenalidomide for maintenance therapy in patients with diffuse large b-cell lymphoma at high risk of central recurrence: a prospective clinical study

Recruiting
4
100
 
Lenalidomide, 25 mg, orally, two weeks ;placebo
Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self financing
lymphoma
 
 
ACTRN12620000291987p: An ALLG Trial to compare the use of Selinexor, Lenalidomide and Dexamethasone with Lenalidomide alone for patients with newly diagnosed Multiple Myeloma undergoing Autologous stem cell transplant.

Not yet recruiting
3
232
 
Australian Leukeamia and Lymphoma Group (ALLG), Karyopharm Therapeutics, Inc
Multiple Myeloma
 
 
NCT00098475: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Active, not recruiting
3
452
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
11/08
10/25
NCT01093196 / 2008-008606-52: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Completed
3
660
Europe
Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide, dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma
11/12
07/24
CALGB-100104, NCT00114101: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Checkmark Data presentation from CALGB 100104 study for NDMM at ASCO
Jun 2017 - Jun 2017: Data presentation from CALGB 100104 study for NDMM at ASCO
Checkmark P3 data
May 2012 - May 2012: P3 data
Active, not recruiting
3
460
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Placebo Administration
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
12/12
02/26
NCT00602641: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
3
306
US, RoW
Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Sedoval K17, Softenon, Synovir, Talimol, Thalomid
National Cancer Institute (NCI)
Multiple Myeloma
01/14
02/26
ACTRN12611000085976: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

Active, not recruiting
3
80
 
Australasian Leukaemia and Lymphoma Group, GELA, Australasian Leukaemia and Lymphoma Group, Celgene Global
Diffuse large B cell lymphoma (DLBCL) in elderly patients
 
 
ACTRN12612001045808: A Phase 3 open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (ALLG NHL27)

Completed
3
1000
 
The Lymphoma academic research organisation, Australasian Leukaemia and Lymphoma Group
follicular lymphoma
 
 
2005-001554-24: INTERET D’UN TRAITEMENT D’ENTRETIEN PAR REVLIMID APRES AUTOGREFFE DE CELLULES SOUCHES CHEZ LES PATIENTS DE MOINS DE 65 ANS ATTEINTS DE MYELOME(Essai de phase III, multicentrique, randomisé, double aveugle, versus placebo)

Ongoing
3
40
Europe
Revlimid Lenalidomide, CC-5013, REVLIMID (LENALIDOMIDE), REVLIMID (LENALIDOMIDE)
CHU de TOULOUSE
Myélome de novo stade DS : III, II, I with one symptomatic bone ogique) No sign of cardia insufficiency and echography must schow FEV> 40 %. no hepatic insufficiency : bilirubine< 35µmol/L and SGOT,SGPT, alkaline phosphatases lower than 4 N. No respiratory insufficiency : DLCO >50 % N. no previous kidney insufficiencey non related to the disease and defined bycréatinine >160 µmol/L. Sérology HIV- Myélome de novo De stade DS : III, II, I avec 1 lésion osseuse symptomatique (radiologique) Pas de signes cliniques d\'insuffisance cardiaque ou coronarienne et au plan échographique FEV> 40 %. Pas d’atteinte hépatique : bilirubine< 35µmol/L et des SGOT, des SGPT, des phosphatases alcalines inférieures à 4 N. Pas d’atteinte respiratoire : tests ventilatoires et DLCO >50 % N. Pas d’atteinte rénale antérieure non liée à la maladie et définie par une créatinine >160 µmol/L. Sérologie HIV-
 
 
2007-004007-34: Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide Een gerandomiseerde fase III studie bij niet eerder voorbehandelde patienten met Multipel Myeloom, die niet in aanmerking komen voor hoge dosis chemotherapie, naar het effect van Melfalan Prednison en Thalidomide, gevolgd door onderhoudsbehandeling met Thalidomide versus Melfalan Prednison en Lenalidomide, gevolgd door onderhoudsbehandeling met Lenalidomide.

Ongoing
3
500
Europe
Revlimid, Thalidomide Celgene, Revlimid, Thalidomide Celgene
HOVON Foundation, Dutch Cancer Society, Celgene,
Multiple Myeloma
 
 
2007-003945-33: A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Randomisierter Vergleich von 25 mg versus 5 mg Lenalidomid als Erhaltungstherapie nach Hochdosistherapie und autologer Blutstammzelltransplantation bei Patienten mit Multiplen Myelom

Ongoing
3
194
Europe
Revlimid (5 mg), Revlimid (10mg), Revlimid (25mg), Revlimid (5 mg), Revlimid (10mg), Revlimid (25mg)
Gesellschaft für Medizinische Innovation –Hämatologie und Onkologie mbH (GMIHO), Fa. Celgene
Patients with multiple myeloma Multiples Myelom
 
 
2008-004083-39: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma

Ongoing
3
348
Europe
Dexamethasone, Melphalan, d, Mel, Revlimid, Revlimid
GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
primary treatment of multiple myeloma patients of age 60 till 75 years
 
 
2009-016871-32: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Ongoing
3
700
Europe
REVLIMID (LENALIDOMODE), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB)
CHU de TOULOUSE, , PHRC National/Ministère de la Santé, Celgene International SARL, Janssen Pharmaceutica NV, Amgen
Myeloma, Multiple Myeloma
 
 
2010-019173-16: Randomisierte Phase III Studie für Patienten mit Multiplem Myelom zur Untersuchung zweier Therapieschemata einer Bortezomib-basierten Induktionsthearpie und einer Lenalidomid-Konsolidierungstherapie gefolgt von einer Erhaltungstherapie mit Lenalidomid

Ongoing
3
604
Europe
Lenalidomide, CC-5013, Velcade, Revlimid, Velcade, Revlimid
University Hospital Heidelberg, Fa. Janssen-Cilag GmbH, Neuss, Fa. Celgene, München, Fa. Chugai, Frankfurt am Main, The Binding Site, Schwetzingen
multiple myeloma (symptomatic, newly diagnosed)
 
 
2009-013856-61: Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/Dexamethason versus Lenalidomid/Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiviertem Multiplen Myelom

Ongoing
3
282
Europe
autologous PBSC, CD34+ cells, Revlimid®, Revlimid®
University Hospital Heidelberg, Amgen, Celgene, Chugai, Hopp-Foundation
Multiple Myeloma (1.-3. Progression/Relapse)
 
 
2010-021557-40: A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE III DI CONFRONTO TRA BORTEZOMIB, CICLOFOSFAMIDE E DESAMETASONE RISPETTO A LENALIDOMIDE, CICLOFOSFAMIDE E DESAMETASONE IN PAZIENTI CON MIELOMA MULTIPLO IN PRIMA RICADUTA.

Ongoing
3
200
Europe
VELCADE, SOLDESAM, ENDOXAN BAXTER*INIET 1FL 500MG, REVLIMID*21CPS 15MG, REVLIMID*21CPS 10MG, REVLIMID*21CPS 5MG, VELCADE, SOLDESAM, ENDOXAN BAXTER*INIET 1FL 500MG, REVLIMID*21CPS 15MG, REVLIMID*21CPS 10MG, REVLIMID*21CPS 5MG
ISTITUTO NAZIONALE PER LA CURA TUMORI, ministero della salute
Multiple mieloma Mieloma multiplo
 
 
2014-003079-40: Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment Studie für Patienten mit zuvor unbehandeltem Multiplem Myelom zur Untersuchung der Wirksamkeit von Elotuzumab im Rahmen einer Induktions- und Konsolidierungstherapie mit Bortezomib/Lenalidomid/Dexamethason sowie in der Erhaltungstherapie mit Lenalidomid

Ongoing
3
516
Europe
Lenalidomide, Elotuzumab, CC-5013, BMS-901608, formerly known as HuLuc63, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg, Celgene International Sarl, Bristol-Myers Squibb International Corporation
Newly diagnosed symptomatic multiple myeloma symptomatisches Multiples Myelom, Primärtherapie
 
 
POLLUX, NCT02076009 / 2013-005525-23: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Checkmark Four-year follow up data from trial for multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Four-year follow up data from trial for multiple myeloma at ASH 2019
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Update from POLLUX trial for r/r multiple myeloma at ASH 2018 [screenshot]
Checkmark Update from POLLUX trial for r/r multiple myeloma at ASH 2018
More
Completed
3
569
Europe, Canada, Japan, US, RoW
Daratumumab, Lenalidomide, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
03/16
11/24
SWOG S0777, NCT00644228: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Checkmark From SWOG 0777 trial at ASH 2015
Dec 2015 - Dec 2015: From SWOG 0777 trial at ASH 2015
Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Active, not recruiting
3
525
US, RoW
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
11/15
09/25
NCT01685814 / 2009-016616-21: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Active, not recruiting
3
406
Europe
Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant
Wuerzburg University Hospital, ClinAssess GmbH, Celgene Corporation
Previously Untreated Symptomatic Multiple Myeloma
09/16
12/23
2015-002380-42: Research study to determine whether a combination of 3 drugs calledlenalidomide, carfilzomib and dexamethasone given to persons afterautologous stem cell (a young cell without a specific purpose from whichother cell types develop) transplant is better than lenalidomidemaintenance alone. Badanie Kliniczne prowadzone celem ustalenia czy kombinacja trzechleków o nazwie lenalidomid, carfilzomib i dexametazon podana osobom poautologicznej transplantacji komórek macierzystych (pierwotne,niewyspecjalizowane komórki nie posiadające określonego przeznaczenia,które mają zdolność do przekształcania się w wyspecjalizowane komórki)jest skuteczniejsza niż podawanie samego leku lenalidomid.

Ongoing
3
180
Europe
Dexamethasone, Capsule, hard, Powder for solution for infusion, Tablet, Revlimid, Kyprolis
Polish Myeloma Consortium, University of Chicago, Celgene Europe Ltd
Multiple Myeloma Szpiczak Mnogi, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała)., Diseases [C] - Cancer [C04]
 
 
2016-004010-10: A Phase 3 evaluation of how PET scans can help guide further therapy or no therapy for patients with previously untreated, high tumour burden follicular lymphoma

Ongoing
3
840
Europe
Rituximab (for intravenous infusion), Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg), Concentrate for solution for infusion, Capsule, hard, Solution for injection, Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg)
University of Liverpool, Cancer Research UK
Previously untreated, high tumour burden follicular lymphoma, Follicular lymphoma is a cancer of the immune system. The cancerous cells accumulate mainly in lymph glands which become swollen. It is incurable and therefore requirement multiple lines of treatment., Diseases [C] - Cancer [C04]
 
 
NCT02257515: Stem Cell Transplant and Lenalidomide With and Without Bortezomib in Treating Patients With Multiple Myeloma

Active, not recruiting
3
750
US
lenalidomide, CC-5013, IMiD-1, Revlimid, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, bortezomib, LDP 341, MLN341, VELCADE, quality-of-life assessment, quality of life assessment, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, autologous-autologous tandem hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
12/17
 
2017-002290-19: Rituximab maintenance will be compared to “lenalidomide plus rituximab maintenance followed by lenalidomide only maintenance” for relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Not yet recruiting
3
450
Europe
Capsule, hard, Concentrate for solution for infusion, Revlimid 2.5mg, hard capsules, Revlimid 5mg, hard capsules, Revlimid 10mg, hard capsules, Revlimid 15mg, hard capsules, Revlimid 20.0 mg, hard capsules, MabThera 500mg, concentrate for solution for infusion
Celgene Corporation, Celgene Corporation
relapsed/refractory follicular, marginal zone or mantle cell lymphoma, Three types of blood cancer called lymphoma, Diseases [C] - Cancer [C04]
 
 
MAIA, NCT02252172 / 2014-002273-11: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Checkmark Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from MAIA trial in combination with Revlimid for multiple myeloma at ASH 2022
Checkmark From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Jun 2021 - Jun 2021: From MAIA trial in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma at EHA 2021
Checkmark Data from trial in combination with Revlimid for multiple myeloma at ASH 2020
More
Completed
3
737
Europe, Canada, US, RoW
Daratumumab IV, JNJ-54767414, Lenalidomide, Dexamethasone, Daratumumab SC
Janssen Research & Development, LLC
Multiple Myeloma
09/18
10/24
2018-004330-15: A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma Étude de phase III randomisée, multicentrique, comparant l’administration continue ou pour une durée fixe de l’association daratumumab, lenalidomide et dexaméthasone dans le myélome multiple en rechute

Not yet recruiting
3
434
Europe
Daratumumab, Lenalidomide, Dexamethasone, Solution for infusion, Capsule, hard, , DARZALEX, REVLIMID
Assistance Publique - Hôpitaux de Paris (AP-HP), Inca
multiple myeloma myelome multiple, myeloma myelome, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01169337: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Checkmark ECOG E3A06 study
Oct 2018 - Oct 2018: ECOG E3A06 study
Active, not recruiting
3
226
Europe, US
Clinical Observation, observation, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Light Chain Deposition Disease, Smoldering Multiple Myeloma
01/19
03/26
 

Download Options